Trastuzumab pamirtecan clinical trials
How each study uses trastuzumab pamirtecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trastuzumab pamirtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
DualityBio Inc. (3) · BioNTech SE (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test trastuzumab pamirtecan.
- Aug 2027A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPhase 1/2 · DualityBio Inc.
Studies
Open first, then newest update. How each study uses trastuzumab pamirtecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerRecruitingPhase 3BioNTech SENCT06340568Written as BNT323/DB-1303
- A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerRecruitingPhase 1/2BioNTech SENCT06827236Written as BNT323
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05150691Written as DB-1303/BNT323
- A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerActive, not recruitingPhase 3DualityBio Inc.NCT06265428Written as DB-1303/BNT323
- A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Active, not recruitingPhase 3DualityBio Inc.NCT06018337Written as DB-1303/BNT323
Codes
What other systems call trastuzumab pamirtecan · ClinicalTrials.gg INT018374
- UNII (FDA) WPL7XBK5KUTRASTUZUMAB PAMIRTECANOne source FDA
- NCI Thesaurus C188319Trastuzumab PamirtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WPL7XBK5KU | TRASTUZUMAB PAMIRTECAN | One source FDA |
| NCI Thesaurus | C188319 | Trastuzumab Pamirtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.